Evaluation of the decolonization rate and acceptance of a complete nasal decolonization kit with povidone iodine for MRSA patients (MRSAD-PVP-I)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500642-25-00

Acronym

RC21_0556

Enrollment

Registered

2023-01-17

Start date

2024-11-21

Completion date

2025-12-04

Last updated

2023-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MRSA patients

Brief summary

MRSA nasal decolonization: Negative nasal screening rate 6 hours after use of the kit

Detailed description

Acceptability by the patient and HCWs of the use of the complete kit by a satisfactory self-questionnaire, Characteristics of patients remained MRSA positive after PVP-I decolonization, List of adverse events reported by patients, MRSA nasal decolonization: Negative nasal screening rate 24 hours after use of the kit.

Interventions

DRUGBETADINE 10 POUR CENT

DRUGsolution pour bain de bouche

DRUGgel

DRUGBETADINE SCRUB 4 POUR CENT

DRUGsolution pour application cutanée (moussante)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MRSA nasal decolonization: Negative nasal screening rate 6 hours after use of the kit	—

Secondary

Measure	Time frame
Acceptability by the patient and HCWs of the use of the complete kit by a satisfactory self-questionnaire, Characteristics of patients remained MRSA positive after PVP-I decolonization, List of adverse events reported by patients, MRSA nasal decolonization: Negative nasal screening rate 24 hours after use of the kit.	—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026